Synovus Financial Corp Sells 13,347 Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH)

Synovus Financial Corp lowered its holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 37.1% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 22,601 shares of the medical equipment provider's stock after selling 13,347 shares during the quarter. Synovus Financial Corp's holdings in Lantheus were worth $2,481,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in the business. Wilmington Savings Fund Society FSB acquired a new stake in shares of Lantheus in the 3rd quarter valued at $25,000. Signaturefd LLC increased its holdings in shares of Lantheus by 40.5% during the third quarter. Signaturefd LLC now owns 319 shares of the medical equipment provider's stock worth $35,000 after buying an additional 92 shares in the last quarter. Nkcfo LLC bought a new position in shares of Lantheus in the second quarter valued at approximately $47,000. UMB Bank n.a. grew its position in Lantheus by 42.1% during the 3rd quarter. UMB Bank n.a. now owns 425 shares of the medical equipment provider's stock worth $47,000 after acquiring an additional 126 shares during the last quarter. Finally, Kathleen S. Wright Associates Inc. acquired a new stake in Lantheus during the 3rd quarter valued at $51,000. Institutional investors and hedge funds own 99.06% of the company's stock.

Lantheus Price Performance

Shares of Lantheus stock traded up $0.46 on Monday, hitting $93.48. 838,539 shares of the company's stock traded hands, compared to its average volume of 1,012,044. The firm's 50-day moving average price is $97.62 and its two-hundred day moving average price is $98.20. The stock has a market capitalization of $6.50 billion, a PE ratio of 15.55 and a beta of 0.45. Lantheus Holdings, Inc. has a one year low of $50.20 and a one year high of $126.89.

Analysts Set New Price Targets

LNTH has been the subject of a number of research reports. StockNews.com lowered Lantheus from a "buy" rating to a "hold" rating in a research note on Thursday, November 21st. JMP Securities reduced their target price on shares of Lantheus from $125.00 to $112.00 and set a "market outperform" rating on the stock in a research report on Thursday, November 7th. Truist Financial restated a "buy" rating and issued a $120.00 price objective (down previously from $135.00) on shares of Lantheus in a research report on Friday, November 8th. Finally, Redburn Atlantic began coverage on Lantheus in a research report on Tuesday, September 3rd. They issued a "buy" rating and a $175.00 price objective on the stock. Two analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $130.00.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.